TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Ratio of patients receiving medication assisted treatment to the number of patients with opioid use disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of providers prescribing medication assisted treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Neglect symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neglect-related functional disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety and tolerability of NIM811
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in markers of bacterial translocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in markers of immunoactivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in markers of endothelial dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biodistribution of 89Zr-atezolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Calcium Oxalate crystallization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Patient Reported Hip Dysfunction and Osteoarthritis Outcome Score (HOOS) Survey
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Structural healing integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHO Ordinal Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the activity score of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Free From VT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients with metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference in CD45RO+ tumor infiltrating lymphocytes (TILs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tmax of serum cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity profile of ET019002T-cell treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Hepatitis C Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of wound infections
Endpoint domain: Adverse events/effects
Primary endpoint: Level of competency achieved
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Safety and tolerability as indicated by adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change From Baseline in the Eczema Area and Severity Index (EASI) Total Score at Day 29
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Discontinuations Due to AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Changes in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Intestinal Chemosensitivity to Lipids Perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Passive range of motion of the lower limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serum Sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in retinal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inventory of Depressive Symptomatology, Self Report (IDS-SR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Alkaline Phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Aspartate Aminotransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Alanine Aminotransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Adequate Clinical and Parasitological Response (ACPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (CR, CRi, PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hospital-requiring respiratory infections
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Length of Exercise Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of HCM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean number of asthma exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sleep quality of Rheumatoid arthritis patients
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Duration to reach intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Accuracy of capsule endoscopy for detecting esophageal varices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Early Asthmatic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Performance Quality Rating Scale (PQRS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mayo-Portland Adaptability Inventory (MPAI-4)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change from baseline on Social skills at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change from baseline on Externalizing symptoms at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline FASD severity at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Birth weight of newborn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Causes of morbidity
Endpoint domain: Mortality/survival
Primary endpoint: Area under the serum concentration-time curve (AUC) from 0 to final sampling time point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from 0 to infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of device-related or PMMA-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Successful radiographic fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole Blood Manganese
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in patient quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Annualized Bleeding Rate (ABR) pre and post-tailoring implementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain change over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the distal view of the tooth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Laboratory Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Assessments by RESIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Blood Borne Pathogen Transmission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Presence of Diastasis Recti Abdominus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall Benefit of Anesthesia Score (OBAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in Serum Alanine Transaminase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Mental Health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Urinary Glycosaminoglycan (GAG) Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Distance Traveled
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Neurocognitive Ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: PANSS negative symptoms factor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: TG Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in ALSFRS-R score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of BAY2416964
Endpoint domain: Adverse events/effects
Primary endpoint: Anesthetists non technical skills (ANTS) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stent complications
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of responders at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of Pain Intensity Difference (SPID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Bayley III motor scales scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Clinically Significant Prostate Cancer
Endpoint domain: Mortality/survival
Primary endpoint: Low protein activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DMFT/dft index value changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of dexmedetomidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of uterine electromyographic (EMG) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change from baseline in ACR20 response at week 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in modified van der Heijde-Sharp Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Melanocyte cell quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in bone quality parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Conduit artery endothelial-dependent dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in score of alertness test (TAP)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Effective Mandibular Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective maxillary length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients interrupting treatment due to virological failure
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse drug reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Acute hemodynamic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Full hemodynamic response to beta blockers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Full hemodynamic response to beta blockers plus rosuvastatin or placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improved depression outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved medical treatment adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enhanced speech in noise perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Underwent TOLAC Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Rate of subjects with solicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Lp-PLA2 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Vitamin D level (25-OHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visual Analog Scale Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Satisfaction: Rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: LogEC50 Platelet Aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Impact on personal identity
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percentage of Participants Meeting Serum Total Testosterone Average Concentration Criteria for Responder During the 3rd Injection Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum Total Testosterone Average Concentration During the 3rd Injection Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum Total Testosterone Maximum Concentration During the 3rd Injection Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Range of motion of operative segments and adjacent segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to treatment as assessed by mobility via the Tomita mobility scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response rate (stabilization and response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: measurement of blood-based biomarkers to predict disease activity 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: measurement of blood-based biomarkers to predict disease activity 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: measurement of blood-based biomarkers to predict disease activity 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Five-Minute Speech Sample (FMSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All Cause and Cause-specific Death
Endpoint domain: Mortality/survival
Primary endpoint: Deaths Within 30 Days of Protocol Treatment Discontinuation
Endpoint domain: Mortality/survival
Primary endpoint: Change in Signal Intensity of Proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in mean Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infant HIV infection status
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity and specificity of AI in detecting diabetic retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Testosterone bioequivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Estradiol bioequivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Limb Morphology and Changes in Muscle Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of Motor Activation of AMI Muscles and Volitional Control of Phantom Limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cisatracurium consumption rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Positive intraocular infection
Endpoint domain: Adverse events/effects
Primary endpoint: mean value of fold-change resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to sustainable return to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Probability of return to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Parent Reported Frequency of Parent-child Communication About Relationships, Sex, and Media
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Child Reported Frequency of Parent-child Communication About Relationships, Sex, and Media
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Empowerment
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Accuracy of Methemoglobin Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Stroke or systemic embolism (SSE)
Endpoint domain: Mortality/survival
Primary endpoint: Effectiveness of aminocamptothecin in treating non-small cell lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of subjects who seroconvert to HPV 6, 11, 16, 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to 30-day hospital readmission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in average FEV1 AUC0-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safe dose determination of GR-MD-02
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in quadriceps muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Degree of lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall health-related functioning
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Transfer of Skills to Clinical Colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Peak Nasal Inflammatory Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual National Total Socioeconomic Cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Score for Satisfaction of Patient
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Insulin Resistance Score Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Deaths Among Recipients of the Cryoablation
Endpoint domain: Mortality/survival
Primary endpoint: Number of Adverse Events Related to the Cryoablation
Endpoint domain: Adverse events/effects
Primary endpoint: Candida Albicans growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Wall to lumen ratio of fundus vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Impact on family
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Time to All-cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Time to Re-hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: UDS results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assisting Hand Assessment (AHA)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Efficacy of eradication therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Chemotherapy-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Success of Investigator's Global Assessment (IGA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to reach BIS > 80
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Duration of Self-Completion of ESAS
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Regional ventilation and perfusion distribution ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Global mechanical compliance and regional impedance compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-Minute Walk Test (6-MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 Quality of Life Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants Alive at 1 Year After Transplant
Endpoint domain: Mortality/survival
Primary endpoint: ECT-induced seizure duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Clara cell protein blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes